Related Experiment Videos
Left ventricular function in thalassemia major: protective effect of deferoxamine
A Desideri1, G Scattolin, A Gabellini
1Cardiology and Transfusion Center, Este General Hospital, Padova, Italy.
The Canadian Journal of Cardiology
|January 1, 1994
Summary
Deferoxamine prevents diastolic dysfunction in thalassemia major patients with transfusional iron overload. However, contractility may decline despite normal ejection fraction, indicating potential systolic impairment even with chelation therapy.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Thalassemia major requires chronic transfusions, leading to iron overload.
- Iron overload can cause significant cardiac dysfunction, particularly affecting the left ventricle.
- Effective chelation therapy is crucial to mitigate iron-related complications.
Purpose of the Study:
- To evaluate the efficacy of deferoxamine in preventing left ventricular systolic and diastolic dysfunction in thalassemia major patients.
- To assess the impact of long-term transfusional iron overload on cardiac function despite chelation therapy.
Main Methods:
- A study involving eight thalassemia major patients and seven age/sex-matched controls.
- Utilized two-dimensional and Doppler echocardiography to assess left ventricular function.
- Patients received chronic transfusional therapy and deferoxamine chelation therapy.
Main Results:
- No significant differences in diastolic function parameters were observed between thalassemic patients and controls.
- Ejection fraction was similar in both groups.
- A slight depression in contractility (end-systolic pressure/end-systolic volume index) was noted in thalassemic patients.
Conclusions:
- Deferoxamine effectively prevents alterations in left ventricular diastolic function in thalassemia major patients undergoing chronic transfusions.
- Depressed contractility, even with a normal ejection fraction, may signal early systolic dysfunction that persists despite chelation therapy.